How should a healthtech startup run PR for a product launch?
A healthtech startup should run launch PR around one clear story, claims its FDA status and evidence can support, and customer proof it has written permission to use. Start eight to ten weeks out. Lock the regulatory wording with counsel, build the press kit, brief trade and specialty reporters under embargo, and publish on your own newsroom page. Then measure demo requests, not clippings.
- Cleared is not approved. A 510(k) device must not be called "FDA approved", and investigational devices cannot be promoted.
- Customer proof needs permission. Use approved organizational quotes and de-identified data, never identifiable patient stories without HIPAA authorization.
- Trade press first, then clinical channels, then business press; consumer press only for D2C products.
- Disclose paid relationships with advisors, clinicians and creators under the FTC Endorsement Guides.
- Every practice welcome — retainers from $499/mo, Goals-Driven engagements, Performance-Linked Payout Models available.
- Dallas, Texas LLC
- US client team · Central Time (CST)
- 25+ US healthcare clients
- BAA signed with every client
- HIPAA compliance training across client and delivery teams
- Contracts and invoices in USD
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
What should a healthtech launch PR plan include?
A launch PR plan needs four things: one clear story about the problem you solve, claims that your regulatory status and evidence can support, proof from real users that you are allowed to share, and a sequence that reaches trade press, buyers and investors in the right order. Most launches fail on the second and third, not the pitching.
Healthtech PR is different from consumer tech PR in one way that shapes everything. Your buyers are clinicians, practice leaders, health system teams or regulated consumers. They read claims carefully. A journalist covering health IT will ask whether the product is cleared, what the evidence is and who uses it. You need those answers written down before the first pitch goes out.
A working timeline
| When | Workstream | Output |
|---|---|---|
| Eight to ten weeks out | Story and claims | Positioning statement, approved claims list, regulatory status wording signed off by counsel |
| Six to eight weeks out | Proof | Customer stories with written permission, de-identified outcome data, spokesperson bios |
| Four to six weeks out | Assets | Press release draft, fact sheet, product images, short demo video, FAQ for reporters |
| Three to four weeks out | Media list and briefings | Target list by outlet type; embargoed briefings booked |
| Launch week | Announcement | Release on your newsroom page, owned channels, sales outreach, customer email |
| Four to twelve weeks after | Follow-through | Bylined articles, conference talks, podcasts, customer webinars, measured results |
The timing flexes with your news. A regulatory clearance has a fixed date you may not control. A feature launch does not. Build the plan around the date you can promise, not the one you hope for.
If the launch is part of a wider go-to-market push, PR should sit inside the full launch marketing plan rather than run on its own track.
What can a healthtech company claim in a launch announcement?
Only what your regulatory status and evidence support. FDA-cleared devices must not be described as "FDA approved". Investigational devices cannot be promoted at all. Wellness products should not name diseases. And any health benefit claim needs competent and reliable scientific evidence under FTC standards, whatever the regulatory path.
The cleared-versus-approved mistake is the most common one in launch releases. Under 21 CFR 807.97, a 510(k) clearance "does not in any way denote official approval of the device," and any representation that creates an impression of official approval "is misleading and constitutes misbranding." So "FDA cleared" is correct for a 510(k) device. "FDA approved" is reserved for products that went through approval pathways.
Products still in clinical study face a harder line. 21 CFR 812.7 says a sponsor, or anyone acting for it, shall not "promote or test market an investigational device" until FDA has approved it for commercial distribution, and shall not represent that it is safe or effective for the purposes under investigation. A "launch" of an investigational device should usually be framed as a study or partnership announcement, reviewed by regulatory counsel.
| Product status | Language that usually fits | Language to avoid |
|---|---|---|
| 510(k) cleared device | "FDA cleared for [cleared indication]" | "FDA approved", claims beyond the cleared indication |
| Investigational device | "Now enrolling in a clinical study", partnership news | Performance, safety or effectiveness claims; pricing or orders |
| General wellness product | Healthy lifestyle language such as sleep habits or activity | Naming a disease, diagnosis or treatment |
| Software that is not a device | Workflow, efficiency, scheduling, documentation claims you can measure | Clinical outcome claims without evidence |
FDA reissued its General Wellness: Policy for Low Risk Devices guidance in January 2026. It is the reference for wellness products that want to stay outside device rules. Read the current version, and have regulatory counsel confirm that your wellness wording stays inside it.
For any health benefit, the FTC's Health Products Compliance Guidance sets the evidence bar. It calls randomized, controlled human clinical trials "the most reliable form of evidence." That matters for launches, because the guidance treats promotional statements in press releases and media interviews as advertising.
How can a healthtech startup use customer stories and data safely?
Get written permission from the customer organization, keep patient information out entirely unless there is a valid HIPAA authorization, and use de-identified or aggregate numbers that the customer has approved. If you are a business associate of your customer, you generally cannot use their patients' information for your own marketing without authorization.
Under HIPAA, a covered entity needs written authorization to use or disclose protected health information for marketing, with narrow exceptions (HHS marketing guidance). A business associate's rights to the data come from its contract, and those rarely extend to its own promotion. In practice, that means a vendor should never name or describe an identifiable patient in launch materials.
What a usable customer story looks like
- The organization, with permission. Logos, names and quotes from a practice or health system need a signed release. Your master agreement may forbid publicity unless the customer agrees in writing.
- A named spokesperson. A clinician or operations leader who agreed to be quoted, on what they saw in their own workflow.
- Operational results. Time saved, steps removed, faster scheduling. These are easier to verify and approve than clinical outcomes.
- Clinical results only with evidence. If you cite outcomes, cite a study and describe it accurately, including its limits.
Ask every reference customer what they will say if a reporter calls. A quote in a release that the customer will not repeat on the phone does more harm than no quote.
If you sell to practices, the story they want to hear is about their front desk, their schedule and their margins. Our guide to healthtech marketing to medical practices covers that buyer in detail.
Which outlets and audiences matter for a healthtech launch?
Trade and specialty press first, because that is where buyers look. Then the professional channels clinicians trust, such as society newsletters and conference programs. Business and startup press matter mainly for hiring and fundraising. General consumer press matters only for direct-to-consumer products, and it carries the most claim risk.
| Audience | What they want from the story | Best asset |
|---|---|---|
| Health IT and trade press | What is new, who uses it, how it fits existing systems | Briefing with the founder and a customer, fact sheet |
| Specialty and clinical outlets | Evidence, workflow impact, clinician voice | Clinician spokesperson, study summary |
| Practice and health system buyers | Cost, time, risk, implementation effort | Customer case study, short demo, implementation FAQ |
| Investors and business press | Market, traction you can disclose, team | Founder interview, company backgrounder |
| Consumers (D2C only) | What it does for them, in plain words | Simple explainer, approved benefit claims only |
Pick spokespeople for credibility, not title
A reporter covering clinical software wants to talk to a clinician. A reporter covering business wants a founder. Train both. Give each a one-page brief with approved claims, the regulatory status wording, and three questions they should decline to answer, such as unreleased data or customer names that are not public.
Angles that earn coverage
Product news alone rarely gets a health IT reporter to write. Give them a reason that is bigger than your release. Three angles tend to work. A workflow problem the reporter's readers complain about, with your customer explaining how they fixed it. A policy or reimbursement change that your product helps buyers respond to, explained accurately. Or original, de-identified data from your platform that shows something the market has not seen before, with the method stated plainly. Each angle puts the reader first and the product second, which is what editors want.
For a broader view of how healthcare PR works and what agencies do, see what PR means in healthcare.
How should embargoes, briefings and the press kit work?
Brief a short list of reporters under embargo a week or two ahead, with a clear lift time and a press kit that answers the questions they will ask. Confirm the embargo in writing before you share anything. Publish the release on your own newsroom page at lift time so search engines and AI tools find the original.
The press kit
- Release. Lead with the problem and the news, not the company history. One quote from the founder, one from a customer if approved.
- Fact sheet. What the product does, who it is for, regulatory status in exact words, pricing model if public, availability date.
- Evidence summary. Study design, size and results, in plain words, with a link to the full paper if published.
- Visuals. Product screens with dummy data only. Real patient data in a screenshot can become a privacy incident, and blurring is not a safe fix.
- Bios and headshots. For each spokesperson.
- Reporter FAQ. Data security, how the product handles health information, whether you sign BAAs, and what it costs to implement.
Keep the newsroom page permanent. Bylined articles, podcast appearances and conference talks in the months after launch should all link back to it. That page becomes the reference that search results and AI answers cite when buyers ask what your product is.
When the news is a clearance
Draft the release before the decision letter arrives, with the indication language left as a placeholder. Fill it in from the letter word for word. Do not paraphrase the cleared indication into something broader. Have regulatory counsel approve the final text.
What rules apply to paid experts, advisors and sponsored content?
The FTC Endorsement Guides apply. Any material connection between you and an endorser that the audience would not expect must be disclosed clearly. That includes paid advisors, clinicians with equity, customers who got discounts, and creators who received free product. Sponsored articles must be labeled as advertising.
The Guides are at 16 CFR Part 255. They define an endorsement broadly. A clinician quoted in your release, a key opinion leader posting about the launch, and an advisor speaking on a panel can all be endorsers. Section 255.5 lists material connections, including payment, free or discounted products, early access, and "the possibility of being paid."
- Advisors and investors who are clinicians: disclose the relationship when they speak about the product.
- Paid speaking slots and sponsored webinars: label them as sponsored.
- Customer quotes: disclose discounts, credits or design-partner terms that the reader would not expect.
- Endorsers' claims: you are responsible for them. An endorser cannot say what you could not say yourself.
The FTC rule on consumer reviews and testimonials, in effect since October 2024, also bars fake or misleading testimonials. That covers quotes attributed to people who did not say them or did not use the product.
How should a healthtech startup measure launch PR?
Measure what changes for the business: qualified demo requests, branded search volume, sales cycle conversations that mention the coverage, inbound partner interest, and whether AI assistants describe your product accurately. Coverage counts and impressions are easy to report and rarely tell you whether the launch worked.
- Demand: demo requests and trials by source, compared with the weeks before launch.
- Search: branded searches and visits to the newsroom page.
- Sales: how often prospects mention an article or talk, logged by the sales team.
- AI answers: ask the main assistants what your product does, and check that the regulatory status they repeat is right.
- Quality: whether coverage repeated your approved claims accurately. Correct errors quickly and politely.
Startups often hand PR to an agency and lose the thread between coverage and pipeline. A fractional CMO keeps PR, sales and product messaging in one plan. At Ichelon Consulting US, Santosh Reddy, Partner, serves as fractional CMO for healthtech companies and owns launch plans in the Embedded plan. See the fractional CMO service, our healthcare PR service, or book a call with the US team.
Related pages from the US team
Fractional CMO for healthcare companies
Senior leadership that owns the launch plan from claims to pipeline.
Healthcare PR service
Media relations and thought leadership for US healthcare companies.
Health product launch marketing plan
The full launch plan that PR should sit inside.
Healthtech marketing to practices
What practice buyers need to hear before they book a demo.
Every practice welcome — Goals-Driven engagements from $499/mo
We benchmark your last 90 days, agree monthly goals with you, and track them live on Ichelon Agency OS with a report every Monday. Performance-Linked Payout Models are available. Our US leadership is based in Dallas, and strategy calls run in US business hours.
Common questions
Can a healthtech company say its product is "FDA approved" if it has 510(k) clearance?
No. FDA rules say a 510(k) clearance does not denote official approval, and any statement that creates an impression of approval because of the premarket notification is misleading and is misbranding. Use "FDA cleared" with the exact cleared indication, and have regulatory counsel review the wording before launch.
Can a startup promote a device that is still in a clinical study?
Generally no. FDA rules say a sponsor, or anyone acting for it, may not promote or test market an investigational device until FDA has approved it for commercial distribution, or represent that it is safe or effective for the purposes under study. Announce the study or partnership instead, with counsel review.
How far ahead should a healthtech startup plan launch PR?
Eight to ten weeks is a workable lead time for most launches. That allows time to agree on claims and regulatory wording, gather customer permissions and de-identified data, build the press kit, and brief reporters under embargo. Clearance-driven launches need a draft ready before the FDA decision arrives.
Can a healthtech vendor share patient stories from customer practices in PR?
Not without a valid HIPAA authorization from the patient, and usually it should not try. HIPAA requires written authorization to use protected health information for marketing, and vendors acting as business associates rarely have rights to use customer data for their own promotion. Use approved organizational quotes and de-identified operational results instead.
Do FTC endorsement rules apply to clinicians quoted in a launch?
Yes, if the clinician has a material connection the audience would not expect, such as payment, equity, an advisory role, discounts or free product. The FTC Endorsement Guides require that connection to be disclosed clearly. The company is also responsible for claims endorsers make, so they cannot say what the company could not.
What metrics show whether healthtech launch PR worked?
Look at qualified demo requests, branded search and newsroom visits, how often prospects mention coverage in sales calls, inbound partnership interest, and whether AI assistants describe the product and its regulatory status accurately. Coverage counts and impressions alone say little about whether the launch moved the business.
A note on this guide: it explains marketing practice, not legal advice. Rules on privacy, advertising and insurance change and vary by state, so confirm anything compliance-related with your own counsel.
Launching in the next quarter?
A 30-minute call with the US team. Bring your draft release or claims list. We will flag the wording that needs counsel and the proof you still need to collect.